Irritable bowel syndrome drug market set to grow to $1.6 billion by 2018
The global irritable bowel syndrome (IBS) therapeutics market was valued at $655.8 million in 2010, and is expected to grow at a compound annual growth rate (CAGR) of 11.7% in the forecast period to reach $1.6 billion by 2018, according to a new report from GlobalData.
The high projected growth rate is primarily attributable to a strong pipeline and increasing disease awareness. Increases in the prevalence of the disease and the launch of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the IBS therapeutics market.
Limited treatment options
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze